Public Release: 

New biomaterial for preventing uncontrolled bleeding

BWH bioengineers have developed an injectable material that could offer a better way to prevent bleeding for many patients

Brigham and Women's Hospital

IMAGE

IMAGE: This is an image highlighting the injectability of the biomaterial through a catheter. The biomaterial can maintain its shape upon injection, only becoming liquid after a force is applied. Inset... view more

Credit: Ali Khademhosseini, Brigham and Women's Hospital

To treat an aneurysm, gastrointestinal bleeding or other forms of uncontrolled hemorrhaging, clinicians often use tiny metallic coils, which can be permanently inserted into a blood vessel to prevent further bleeding. But such coils come with limitations. Patients on blood thinning medications or who cannot form blood clots for other reasons can experience dangerous break-through bleeding, with rebleeding occurring in as many as 47 percent of patients. To find a better solution, bioengineers from Brigham and Women's Hospital, led by Ali Khademhosseini, PhD, collaborated with Rahmi Oklu MD, PhD, FSIR, a clinician who is an interventional radiologist (previously at Massachusetts General Hospital, now at Mayo Clinic). Khademhosseini and Oklu's team develop a rapidly deployable hydrogel that can hold its shape within a blood vessel to prevent bleeding, even in those who cannot form blood clots. The newly developed agent is described in a paper published in Science Translational Medicine Nov. 16.

"This work is an example of how bioengineering can help address the challenges that clinicians and patients face," said Khademhosseini. "Our work thus far has been in the lab, but we are on a translational path to bring this new biomaterial for embolization to the clinic to improve patient care."

The new agent, known as a shear-thinning biomaterial (STB), has a consistency similar to toothpaste and is made up of both gelatin - which gives it gel like properties - and nanoparticles. Using a catheter, the material can be flowed into a blood vessel but is able to maintain its shape once inside the vessel, obstructing the vessel or aneurysm without relying on the formation of a blood clot. Mechanical testing in the lab was initially performed and monitored the STB's changes over time to optimize the material's properties in animal models. The team then tested the STB in both rodent and porcine models, the latter of which have blood vessels of similar dimensions to human blood vessels.

Some of the beneficial properties of the STB include its ability to withstand pressure within the blood vessel, remain at the site of injection and naturally degrade over time. In addition, the team found that the material attracted cells to migrate and deposit themselves at the site of the STB, helping to block the vessel. The individual component materials that make up the STB have been previously used in humans making their subsequent regulatory process and clinical use easier.

As a next step, the team hopes to begin clinical trials to test the safety and efficacy of the STB for use in humans.

###

This work was supported by the National Institutes of Health, U.S. Army Research Office, National Science Foundation, Sloan Foundation and Mayo Clinic.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.